The stock's rise snapped a four-day losing streak.

Rob Sechan, CEO of NewEdge Wealth, joins CNBC's "Halftime Report" to detail his many portfolio moves.

Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

BMO Capital analyst Daniel Jester lowered the firm’s price target on Vertex (VERX) to $41 from $56 and keeps a Market Perform rating on the ...

DA Davidson analyst William Jellison lowered the firm’s price target on Vertex (VERX) to $55 from $62 and keeps a Buy rating on the shares.

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...

We recently compiled a list of the 10 Stocks Drop by Double Digits Mostly Due to Disappointing Earnings. In this article, we ...

Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, today announced the ...

KING OF PRUSSIA, Pa. — KING OF PRUSSIA, Pa. — Vertex, Inc. (VERX) on Thursday reported a loss of $67.8 million in its fourth quarter. On a per-share basis, the King Of Prussia, Pennsylvania-based ...

Arc’teryx has introduced four new technical models to its footwear roster: Norvan LD 4, Vertex Speed, Norvan Nivalis, Konseal ...

Arc'teryx’s new footwear models will be available globally, launching throughout 2025. The Norvan LD 4 arrives in March, ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...